.
├─vaccines_pertussis_vaccine_antibody_immunity
│    ├─chlamydia_t_levels_trachomatis_chlamydia trachomatis
│    │    ├─chlamydia_trachomatis_chlamydia trachomatis_protective immunity_t cells
│    │    │    ├─■──cholera_year_obstacles clemens_clemens trial_protective vaccination ── Topic: 10
│    │    │    └─■──chlamydia_chlamydia trachomatis_trachomatis_tularemia_tularemia cd8 ── Topic: 19
│    │    └─levels_rts_malaria_antibodies_t cell
│    │         ├─■──rts_malaria_malaria vaccine_t cell_cell responses ── Topic: 0
│    │         └─■──levels_higher_high levels_antibodies_times ── Topic: 7
│    └─pertussis_vaccines_inactivated_antibody_dose
│         ├─pertussis_inactivated_dose_respiratory_acellular
│         │    ├─pertussis_acellular_pertussis vaccine_dose_pertussis vaccines
│         │    │    ├─■──pertussis_pertussis vaccine_acellular_pertussis vaccines_bordetella ── Topic: 2
│         │    │    └─■──dose_live vaccine_%_recipients infected_killed vaccine ── Topic: 6
│         │    └─rotavirus_influenza_attenuated_rate_inactivated influenza
│         │         ├─influenza_rate_inactivated influenza_nasal_respiratory
│         │         │    ├─■──respiratory_syncytial_respiratory syncytial_nasal_mucosal ── Topic: 11
│         │         │    └─■──inactivated influenza_rate_influenza_attenuated inactivated_influenza vaccine ── Topic: 13
│         │         └─■──rotavirus_rit attenuated_rit_attenuated bovine_monovalent inactivated ── Topic: 16
│         └─rubella_rubella vaccines_diseases_rev vaccines_diseases vaccine
│              ├─■──systems_biology_fever vaccine_systems biology_yellow fever ── Topic: 22
│              └─rubella vaccines_rubella_diseases vaccine_infectious diseases_infectious
│                   ├─■──rubella_rubella vaccines_neutralization_definitely_immunologic properties ── Topic: 20
│                   └─■──vaccine rev_diseases vaccine_infectious diseases_major infectious_vaccination major ── Topic: 3
└─vaccine_immune_efficacy_hiv-1_trial
     ├─immune_hiv-1_correlates_trials_vaccine
     │    ├─trials_zoster_herpes zoster_herpes_vaccine trials
     │    │    ├─trials_vaccine trials_surrogate_development_vaccine development
     │    │    │    ├─■──permits_measurement_cop_assessing_vaccine critical ── Topic: 17
     │    │    │    └─surrogate_trials_vaccine trials_vaccine development_development
     │    │    │         ├─■──development_efficacy trials_vaccine development_trials_biomarkers ── Topic: 21
     │    │    │         └─■──surrogate_application_gilbert_endpoint_application vaccine ── Topic: 5
     │    │    └─zoster_herpes zoster_herpes_zoster vaccine_ve
     │    │         ├─■──ve_pathogen_biomarker_vaccinees_defined ── Topic: 18
     │    │         └─■──zoster_herpes_herpes zoster_zoster vaccine_excellent ── Topic: 12
     │    └─hiv-1_immune correlates_correlates_correlates protection_induced
     │         ├─correlates protection_protection vaccination_protection_protection induced_correlates
     │         │    ├─■──protection vaccination_correlates protection_mechanism_induced vaccination_protection ── Topic: 1
     │         │    └─■──influenza_immune correlates_attenuated cold_intranasal immunological_assessment influenza ── Topic: 8
     │         └─hiv-1_vaccine efficacy_efficacy trial_hiv-1 infection_trial
     │              ├─■──efficacy trial_trial_hiv-1_vaccine efficacy_vaccine trial ── Topic: 4
     │              └─■──hiv-1_hiv-1 infection_risk_vaccine induced_declines ── Topic: 9
     └─cytomegalovirus_conjugate_conjugate vaccine_controlled_randomised
          ├─■──conjugate vaccine_conjugate_pneumococcal_pneumococcal conjugate_controlled trial ── Topic: 15
          └─■──cytomegalovirus_challenge_study involved_vaccine low_maternal cytomegalovirus ── Topic: 14
